Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Ludvik, B; Giorgino, F; Jodar, E; Frias, JP; Lando, LF; Brown, K; Bray, R; Rodriguez, A

Rodriguez, A (corresponding author), Lilly Spain, Madrid 28108, Spain.

LANCET, 2021; 398 (10300): 583

Abstract

Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索